ARTICLE
31 May 2024

The Pharmacovigilance M&A Market

The global pharmacovigilance (PV) or drug safety market is projected to grow from $8.6bn in 2024 to $22.4bn by 2032.
United Kingdom Corporate/Commercial Law
Al-Munther Sultan’s articles from Alvarez & Marsal are most popular:
  • with readers working within the Business & Consumer Services industries
Alvarez & Marsal are most popular:
  • within Litigation, Mediation & Arbitration and Accounting and Audit topic(s)

The global pharmacovigilance (PV) or drug safety market is projected to grow from $8.6bn in 2024 to $22.4bn by 2032.

Fundamental drivers shaping this growth include:

  • Growing levels of drug consumption with increasing complexity of drugs being developed
  • Increasingly stringent regulatory mandates and complex compliance requirements
  • Technological advancements driving efficiencies in the PV market
  • Continued trend of outsourcing in the pharma services industry, including of PV services

Anticipating an exciting growth outlook, the demand for pharmacovigilance (PV) is poised to fuel increased M&A activity.

To learn more about the key M&A trends taking shape this year in the pharmacovigilance space, read our latest paper.

DOWNLOAD THE FULL PAPER

Originally Published 30 May 2024

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More